Why the study?
Regulating and resolving adverse inflammation driven by FPR2 is postulated to improve outcomes in heart disease, but emerging concepts and strategies require synthesis.
FPR2 agonists represent an emerging therapeutic strategy to resolve adverse inflammation and prevent maladaptive remodeling in heart disease.
Formyl peptide receptor type 2 (FPR2) regulates the initiation and resolution phases of the inflammatory response. In the setting of heart injury and disease, dysregulated inflammation can potentiate maladaptive healing and pathological remodeling of the heart leading to cardiac dysfunction and failure. The potential to regulate and resolve adverse inflammation is postulated to improve outcome in the setting of heart disease. This review covers emerging concepts on the role of FPR2 in heart disease and strategies to activate pro-resolution processes to limit disease progression. We summarize key preclinical studies that support use of FPR2 agonists in heart disease. Finally, we briefly discuss the status of FPR2 agonists under evaluation in the clinic.
No takes yet. Share an insight, caveat, or question.
Lupisella et al. (2022) conducted a review in Heart disease. FPR2 agonists was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: